Literature DB >> 9587063

Clinical and molecular aspects of nephropathic cystinosis.

G A McDowell1, M M Town, W van't Hoff, W A Gahl.   

Abstract

Nephropathic cystinosis, an autosomal recessively inherited lysosomal storage disease, results from impaired transport of the disulfide amino acid cystine out of cellular lysosomes. The consequent accumulation and crystallization of cystine destroys tissues, causing growth retardation in infancy, renal failure at 10 years of age, and a variety of other complications. Early oral therapy with the cystine-depleting agent cysteamine prevents renal deterioration and enhances growth. Although the lysosomal cystine carrier has been extensively studied, its molecular structure remains unknown. The lysosomal cystine transporter gene has been mapped by linkage analysis to human chromosome 17p between polymorphic microsatellite markers D17S1583 and D17S1584. Pertinent recombination events and homozygosity by descent has verified that the cystinosis gene lies in the 3.6 cM genetic interval between these two markers. The cystinosis region has been substantially reduced in size by the observation of recombination events in cystinosis patients between markers D17S1828 and D17S2167. According to radiation hybrid analysis, these two markers are separated by 10.2 cR8000 (centirad using 8000 rad radiation hybrids). Estimates of the physical size of this interval range from 187 to 510 kb. Four yeast artificial chromosomes have been identified which form a contig covering the original cystinosis region. Two P1 clones together may span the new, smaller interval, meaning that the cystinosis gene would lie on one of them. Current efforts are being directed toward using these P1 clones to isolate candidate cDNAs by a variety of methods. The ultimate cloning of the cystinosis gene will reveal how functional lysosomal porters are synthesized, targeted, processed, and integrated into the lysosomal membrane.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9587063     DOI: 10.1007/s001090050220

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  6 in total

Review 1.  Genetic analysis in mice identifies cysteamine as a novel partner for artemisinin in the treatment of malaria.

Authors:  Gundula Min-Oo; Philippe Gros
Journal:  Mamm Genome       Date:  2011-03-25       Impact factor: 2.957

2.  Mitochondrial autophagy promotes cellular injury in nephropathic cystinosis.

Authors:  Poonam Sansanwal; Benedict Yen; William A Gahl; Yewei Ma; Lihua Ying; Lee-Jun C Wong; Minnie M Sarwal
Journal:  J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 10.121

3.  Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients.

Authors:  Eric B Belldina; Mei Y Huang; Jerry A Schneider; Richard C Brundage; Timothy S Tracy
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

Review 4.  Nephropathic cystinosis: late complications of a multisystemic disease.

Authors:  Galina Nesterova; William Gahl
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

5.  Nephropathic cystinosis associated with cardiomyopathy: a 27-year clinical follow-up.

Authors:  Mehul P Dixit; Ira Greifer
Journal:  BMC Nephrol       Date:  2002-11-09       Impact factor: 2.388

Review 6.  Treatment of corneal cystine crystal accumulation in patients with cystinosis.

Authors:  Fatemeh Shams; Iain Livingstone; Dilys Oladiwura; Kanna Ramaesh
Journal:  Clin Ophthalmol       Date:  2014-10-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.